Reply to D. Santini et al

KRAS mutation testing in patients with metastatic colorectal carcinoma: An 18-month experience emphasizing the risk of false-negative results.

(2017) F. Bibeau et al.   JOURNAL OF CLINICAL ONCOLOGY

Should Oncologists Be Aware in Their Clinical Practice ofKRASMolecular Analysis?

(2011) Daniele Santini et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer

(2010) Marc Peeters et al.   JOURNAL OF CLINICAL ONCOLOGY

Detection ofKRASmutations in colorectal carcinoma patients with an integrated PCR/sequencing and real-time PCR approach

(2010) Pietro Carotenuto et al.   PHARMACOGENOMICS

High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue

(2009) Jolien Tol et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer

(2009) Pierre Laurent-Puig et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeted KRAS Mutation Assessment on Patient Tumor Histologic Material in Real Time Diagnostics

(2009) Vassiliki Kotoula et al.   PLoS One

Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

(2008) Rafael G. Amado et al.   JOURNAL OF CLINICAL ONCOLOGY

K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer

(2008) Christos S. Karapetis et al.   NEW ENGLAND JOURNAL OF MEDICINE